Min H. Kang, Pharm. D.
| Associate Professor | min.kang@ttuhsc.edu |
Research Interests
Development and implementation of robust pre-clinical data for testing anti-neoplastic drugs suitable for phase I trials in lymphoid malignancies.
Molecular characterization of mechanisms of resistance to currently employed or potential anti-neoplastic agents in lymphoid malignancies.
History & Education
Degrees
| 1998 | PharmD | University of Colorado Health Science Center |
| BS | Chungbuk National University |
Memberships & Affiliations
- American Association of Cancer Research
- American College of Clinical Pharmacy
- Korean College of Clinical Pharmacy
- Korean Pharmaceutical Association
Publications
- JP Cooper, K Hwang, H Singh, D Wang, CP Reynolds, RW Curley Jr., SC Williams, BJ Maurer, MH Kang. Fenretinide Metabolism in Humans and Mice: Utilizing Pharmacologic Modulation of its Metabolic Pathway to Increase Systemic Exposure. Br. J Pharmacol. (in press).
- MH Kang†, CP Reynolds, PJ Houghton, CL Morton, EA Kolb, R Gorlick, ST Keir, H Carol, R Lock, JM Maris, A Wozniak, MA Smith. Initial Testing (Stage 1) of AT13387, an HSP90 Inhibitor, by the Pediatric Preclinical Testing Program. (submitted) †Correspondence.
- C Zhang, YK Ryu, TZ Chen, C Samathanam, DR Webster, MH Kang. Rapamycin and Dexamethasone are Synergistically Cytotoxic In Vitro and In Vivo for Lymphoid Malignancies with High P70 S6 Kinase1 Activity. Mol Cancer Ther. (provisionally accepted)
- PJ Houghton, CL Morton, MH Kang, CP Reynolds, CA Billups, E Favours, D Payne-Turner, C Tucker, MA Smith. (2010) Evaluation of cytarabine against Ewing sarcoma xenografts by the pediatric preclinical testing program. Pediatr. Blood Cancer. 55, 1224-6.
- H Carol, CL Morton, R Gorlick, EA Kolb, ST Keir, CP Reynolds, MH Kang, JM Maris, C Billups, MA Smith, PJ Houghton, RB Lock. (2010) Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program. Pediatr. Blood Cancer. 55, 1329-37.
- ST Keir, JM Maris, R Lock, EA Kolb, R Gorlick, H Carol, CL Morton, CP Reynolds, MH Kang, A Watkins, PJ Houghton, MA Smith. (2010) Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. Pediatr. Blood Cancer. 55(6):1126-33.
- MH Kang, MA Smith, CL Morton, N Keshelava, PJ Houghton, CP Reynolds. (2010) National Cancer Institute Pediatric Preclinical Testing Program: Model Description for In Vitro Cytotoxicity Testing. Pediatr. Blood Cancer. 56(2):239-49.
- EA Kolb, R Gorlick, PJ Houghton, CL Morton, G Neale, ST Keir, H Carol, R Lock, D Phelps, MH Kang, CP Reynolds, JM Maris, C Billups, MA Smith. (2010) Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer. 55(4),668-77.
- CL Morton, PJ Houghton, EA Kolb, R Gorlick, CP Reynolds, MH Kang, JM Maris, ST Keir, J Wu, MA Smith. (2010). Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program. Pediatr. Blood Cancer. 55, 295-303.
- JS Lee, H Singh, BJ Maurer, CP Reynolds, MH Kang. (2010). A validated LC with fluorescence detection method for simultaneous determination of safingol and D-erythro-sphinganine in human plasma. Chromatographia. 71, 1087-1091.
- PJ Houghton, CL Morton, R Gorlick, EA Kolb, ST Keir, CP Reynolds, MH Kang, JM Maris, J Wu, MA Smith. (2010). Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the pediatric preclinical testing program. Pediatr. Blood Cancer. 54, 921-6.
- JM Maris, CL Morton, R Gorlick, EA Kolb, R Lock, H Carol, ST Keir, CP Reynolds, MH Kang, J Wu, MA Smith, PJ Houghton. (2010). Initial testing of the aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr. Blood Cancer. 55, 26-34.
- PJ Houghton, CL Morton, R Gorlick, RB Lock, H Carol, CP Reynolds, MH Kang, JM Maris, ST Keir, EA Kolb, J Wu, AW Wozniak, CA Billups, L Rubinstein, MA Smith. (2010). Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program. Mol. Cancer Ther. 9, 101-12.
- MA Smith, CL Morton, EA Kolb, R Gorlick, ST Keir, H Carol, R Lock, MH Kang, CP Reynolds, JM Maris, AE Watkins, PJ Houghton. (2010). Initial Testing (Stage 1) of Mapatumumab (HGS-ETR1) by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer. 54, 307-310.
- H Carol, PJ Houghton, CL Morton, EA Kolb, R Gorlick, CP Reynolds, MH Kang, JM Maris, ST Keir, A Watkins, MA Smith, RB Lock. (2010). Initial Testing of topotecan by the pediatric preclinical testing program. Pediatr. Blood Cancer. 54, 707-715.
- PJ Houghton, CL Morton, MH Kang, CP Reynolds, C Billups, E Favours, D Payne-Turner, C Tucker, MA Smith. (2010). Evaluation of Cytarabine Against Ewing Sarcoma Xenografts by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer. 9,101-112.
- MH Kang†, N Harutyunyan, CP Hall, RA Papa, RB Lock. (2009). In vitro and in vivo Activity of Methotrexate and Aminopterin against acute lymphoblastic leukemia and lymphoma. Br. J. Haematol. 145, 389-393. †Correspondence
- C Morton, PJ Houghton, R Gorlick, EA Kolb, RB Lock, H Carol, ST Keir, CP Reynolds, MH Kang, JM Maris, C Billups, MA Smith. (2009). Initial Testing of Aplidin by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer. 53, 509-12.
- MH Kang, CP Reynolds. (2009). Bcl-2 inhibitors:Targeting Mitochondrial Apoptotic Pathways in Cancer. Clin. Cancer Res. 15, 1126-32.
- MH Kang†, Z Wan, YH Kang, RS Sposto, CP Reynolds. (2008). Mechanism of Synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in Acute Lymphoblastic Leukemia Cell Lines: Mcl-1 Inactivation. J. Nat. Cancer Inst. 100, 580-595. †Correspondence
- MH Kang†, YH Kang, B Szymanska, N Yen, U Wilczynska-Kalak, MA Sheard, T Harned, RB Lock, CP Reynolds. (2007). Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood. 110, 2057-2066. †Correspondence
- BI Yoo, KB Ahan, MH Kang, OS Kwon, YS Hong, JJ Lee, HS Lee, JS Ryu, TY Kim, DC Moon, S Song, YB Chung. (2005). Pharmacokinetics of 11-hydroxyaclacinomycin X (ID-6105), a novel anthracycline, after i.v. bolus multiple administration in rats. Arch. Pharm. Res. 28, 476-82.
- BI Yoo, KB Ahan, MH Kang, DC Moon, OS Kwon, HS Lee, JS Ryu, TY Kim, S Song, YB Chung. (2005). HPLC analysis and pharmacokinetic characteristics of 11-hydroxyaclacinomycin X (ID-6105), a novel anthracycline, in rats and beagle dogs. Biol. Pharm. Bull. 28, 688-93.
- SY Yin, JJ Lee, YM Kim, CM Jin, YJ Yang, MH Kang, M Kai, MK Lee. (2004). Effects of (1R,9S)-beta-hydrastine on l-DOPA-induced cytotoxicity in PC12 cells. Eur. J. Pharmacol. 488, 71-7.
- SY Yin, YM Kim, JJ Lee, CM Jin, YJ Yang, JJ Ma, MH Kang, M Kai, MK Lee. (2004). Enantio-selective inhibition of (1R,9S)-and (1S,9R)-beta-hydrastines on dopamine biosynthesis in PC12 cells. Neuropharmacology. 47, 1045-1052.
- EI Kim, MH Kang, MK Lee. (2004). Inhibitory effects of tetrahydropapaverine on serotonin biosynthesis in murine mastocytoma P815 cells. Life Science. 75, 1949-1957.
- SY Yin, JJ Lee, YM Kim, CM Jin, YJ Yang, MH Kang, MK Lee. (2004). Inhibition of L-DOPA-induced increase in dopamine content by (1R,9S)-ß-hydrastine hydrochloride in PC12 cells. Nat. Prod. Sci. 10, 119-123.
- SY Yin, YM Kim, JJ Lee, CM Jin, YJ Yang, KW Lim, MH Kang, MK Lee. (2004). Inhibition of tyrosine hydroxylase by (1R,9S)-ß-hydrastine hydrochloride in PC12 cells. Nat. Prod. Sci. 10, 114-118.
- SE Bates, S Bakke, M Kang, RW Robey, S Zhai, P Thambi, CC Chen, S Patil, T Smith, SM Steinberg, M Merino, B Goldspiel, B Meadows, WD Stein, P Choyke, F Balis, WD Figg, T Fojo. (2004). A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma. Clin. Cancer Res. 10, 4724-33.
- EI Kim, S Yin, MH Kang, JT Hong, KW Oh, MK Lee. (2003). Reduction of serotonin content by tetrahydropapaveroline in murine mastocytoma P815 cells. Neuroscience Letters. 339, 131-134.
- JS Lee, MH Kang, MK Kim, MK Lee, SJ Chung, CK Shim, and YB Chung. (2003). Pharmacokinetic modeling and simulation of the carrier-mediated hepatic transport of organic anions. Yakhak Hoeji 47, 110-119.
- JJ Lee, YM Kim, SY Yin, HD Park, MH Kang, JT Hong, MK Lee. (2003). Aggravation of L-DOPA-induced neurotoxicity by tetrahydropapaveroline in PC12 cells. Biochem. Pharmacol. 66, 1787-95.
- YM Kim, JJ Lee, CM Jin, YJ Yang, MH Kang, MK Lee. (2003). Effects of chelidonine of L-DOPA-induced cytotoxicity in PC12 cells. Kor. J. Pharmacogn. 34, 242-245.
- JJ Lee, YM Kim, CM Jin, YJ Yang, MH Kang, MK Lee. (2003). Effects of protoberberine alkaloids on L-DOPA-induced cytotoxicity in PC12 cells. Yakhak Hoeji. 47, 230-233.
- YM Kim, JJ Lee, SY Yin, Y Kim, JK Lee, YP Yoon, MH Kang, MK Lee. (2002). Inhibitory effect of tributyltin on dopamine biosynthesis in PC12 cells. Neuroscience Letters. 332, 13-16.
- SE Bates, C Chen, R Robey, MH Kang, WD Figg, T Fojo. (2002). Reversal of multidrug resistance: lessons from clinical oncology. Novartis Found. Symp. 243, 83-96; discussion 96-102, 180-5.
- JL Marshall, N Rizvi, J Kauh, W Dahut, M Figuera, MH Kang, WD Figg, I Wainer, C Chaissang, MZ Li, MJ Hawkins. (2002). A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J. Exp. Ther. Oncol. 2, 325-32.
- V Sandor, S Bakke, RW Robey, MH Kang, MV Blagosklonny, J Bender, R Brooks, RL Piekarz, E Tucker, WD Figg, KK Chan, B Goldspiel, AT Fojo, SP Balcerzak, SE Bates. (2002). Phase I Trial of the Histone Deacetylase Inhibitor, Depsipeptide (FR901228, NSC 630176), in Patients with Refractory Neoplasms. Clin. Cancer Res. 8, 718-728.
- I Chico, MH Kang, R Bergan, J Abraham, S Bakke, B Meadows, A Rutt, R Robey, P Choyke, M Merino, B Goldspiel, T Smith, S Steinberg, WD Figg, T Fojo, S Bates. (2001). A Phase I study of infusional paclitaxel in combination with the Pgp antagonist PSC 833 (valspodar). J. Clin. Oncol. 19, 832-842.
- S Bates, MH Kang, S Bakke, B Meadows, P Choyke, M Merino, B Goldspiel, I Chico, T Smith, C Chen, R Robey, R Bergan, WD Figg, T Fojo. (2001). A Phase I study of infusional vinblastine in combination with the Pgp antagonist PSC 833 (Valspodar). Cancer 92, 1577-1590.
- MH Kang, WD Figg, Y Ando, MV Blagosklonny, D Liewehr, T Fojo, SE Bates. (2001). The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6 alpha-hydroxypaclitaxel, a major metabolite of paclitaxel. Clin. Cancer Res. 7, 1610-1617.
- MH Kang, MK Lee. (2001). Advances in management of prostate cancer. Korean J. Clin. Pharmacy. 11, 78-88.
- MH Kang, WD Figg, W Dahut. (1999). Taxanes in Hormone Refractory Prostate Cancer. Cancer Practice 7, 270-272.